Contact Us

Please leave a message

×

Media release

DKSH and CELLINK Announce Strategic Partnership to Advance 3D Bioprinting Solutions in China

Back
DKSH and CELLINK Announce Strategic Partnership to Advance 3D Bioprinting Solutions in China

DKSH has signed a strategic partnership with CELLINK, a global leader in 3D bioprinting and part of BICO Group, to expand access to cutting-edge bioprinting solutions in China. Through its extensive sales network and comprehensive service offerings, DKSH will support CELLINK in strengthening its market presence and advancing biomedical research in the region.

Shanghai, China, March 24, 2025 – DKSH Business Unit Technology, a trusted strategic partner in market expansion services, has signed an agreement with CELLINK, a global leader in 3D bioprinting and part of BICO Group. This collaboration marks a significant step in enhancing the accessibility of CELLINK’s state-of-the-art bioprinting technology for research and academic institutions in China specializing in tissue engineering and regenerative medicine. With strong growth prospects, DKSH will leverage its extensive expertise and service offerings to support the integrity of the value chain for CELLINK’s cutting-edge solutions. 

Under this partnership, DKSH will provide comprehensive marketing and sales, logistic and distributions as well as after-sales services in China. By expanding its reach beyond traditional distribution channels, the agreement will enable CELLINK to accelerate its market presence while reinforcing DKSH’s commitment to driving innovation in the life sciences sector. Through this collaboration, DKSH and CELLINK aim to foster innovation and contribute to the advancement of life sciences in China.

Tomoko Bylund, Head of Sales, Applications, and Support APAC, CELLINK, commented: “We are excited to partner with DKSH to bring our cutting-edge 3D bioprinting technology to a broader audience in China. DKSH’s strong sales network and deep market expertise will help us accelerate adoption and drive growth in this dynamic region.”

Jeff Ouyang, Managing Director, Business Unit Technology, DKSH China, added: “DKSH is proud to be a strategic partner for CELLINK, supporting its expansion in China’s fast-evolving life sciences landscape. Our robust service offerings, from marketing to technical support, ensure the integrity of the value chain while unlocking significant growth opportunities for both organizations.”

About CELINK
CELLINK is enabling the future of health as part of BICO, the world’s leading bio convergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health.  BICO is listed on the Nasdaq Stockholm Main Market under BICO.www.cellink.com 

About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Technology offers complete solutions for specialized scientific and industrial applications. With around 1,820 specialists, the Business Unit generated net sales of CHF 549 million in 2024. www.dksh.com/tec

 

For more information please contact:

DKSH China
Penny Gu
Marketing & Communications Manager
Phone +86 21 5058 8241                
penny.gu@dksh.com    

Downloads

Select a market